Allogene Therapeutics, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Allogene Therapeutics, Inc. (ALLO) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$85.28 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-12
- Allogene Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$42.68M.
- Allogene Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$42.61M.
- Allogene Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$38.81M.
- Allogene Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$41.40M.
- Allogene Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$190.89M.
- Allogene Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$257.59M.
- Allogene Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$327.26M.
- Allogene Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$340.41M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 1 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$42.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$85.28M 10-Q · filed 2026-08-12 | -$124.09M derived: sum of 3 quarters · filed 2026-08-12 | -$165.49M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2026-03-31 | -$42.61M 10-Q · filed 2026-05-13 | -$81.42M derived: sum of 2 quarters · filed 2026-05-13 | -$122.82M derived: sum of 3 quarters · filed 2026-05-13 | -$173.76M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-12-31 | -$38.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$80.21M derived: sum of 2 quarters · filed 2026-03-12 | -$131.15M derived: sum of 3 quarters · filed 2026-08-12 | -$190.89M 10-K · filed 2026-03-12 | |||||
| 2025-09-30 | -$41.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$92.34M derived: sum of 2 quarters · filed 2026-08-12 | -$152.08M 10-Q · filed 2025-11-06 | -$212.01M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-06-30 | -$50.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$110.68M 10-Q · filed 2026-08-12 | -$170.62M derived: sum of 3 quarters · filed 2026-08-12 | -$236.91M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-03-31 | -$59.73M 10-Q · filed 2026-05-13 | -$119.67M derived: sum of 2 quarters · filed 2026-05-13 | -$185.97M derived: sum of 3 quarters · filed 2026-05-13 | -$252.32M derived: sum of 4 quarters · filed 2026-05-13 | |||||
| 2024-12-31 | -$59.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$126.23M derived: sum of 2 quarters · filed 2026-03-12 | -$192.59M derived: sum of 3 quarters · filed 2026-03-12 | -$257.59M 10-K · filed 2026-03-12 | |||||
| 2024-09-30 | -$66.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$132.65M derived: sum of 2 quarters · filed 2025-11-06 | -$197.65M 10-Q · filed 2025-11-06 | -$283.43M derived: sum of 4 quarters · filed 2025-11-06 | |||||
| 2024-06-30 | -$66.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$131.36M 10-Q · filed 2025-08-13 | -$217.14M derived: sum of 3 quarters · filed 2025-08-13 | -$279.42M derived: sum of 4 quarters · filed 2025-08-13 | |||||
| 2024-03-31 | -$65.00M 10-Q · filed 2025-05-13 | -$150.78M derived: sum of 2 quarters · filed 2025-05-13 | -$213.06M derived: sum of 3 quarters · filed 2025-05-13 | -$292.30M derived: sum of 4 quarters · filed 2025-05-13 | |||||
| 2023-12-31 | -$85.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$148.06M derived: sum of 2 quarters · filed 2025-03-13 | -$227.30M derived: sum of 3 quarters · filed 2025-03-13 | -$327.26M 10-K · filed 2025-03-13 | |||||
| 2023-09-30 | -$62.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$141.52M derived: sum of 2 quarters · filed 2024-11-07 | -$241.49M 10-Q · filed 2024-11-07 | -$238.01M 10-Q · filed 2023-11-02 | -$338.76M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | -$79.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$179.20M 10-Q · filed 2024-08-07 | -$176.69M 10-Q · filed 2023-08-02 | -$276.48M derived: sum of 3 quarters · filed 2024-08-07 | -$360.72M derived: sum of 4 quarters · filed 2024-08-07 | ||||
| 2023-03-31 | -$99.97M 10-Q · filed 2024-05-13 | -$98.70M 10-Q · filed 2023-05-03 | -$197.24M derived: sum of 2 quarters · filed 2024-05-13 | -$281.49M derived: sum of 3 quarters · filed 2024-05-13 | -$361.77M derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2022-12-31 | -$97.28M derived: 10-K/A 12 month − 10-K 9 month · filed 2024-03-14 | -$181.52M derived: sum of 2 quarters · filed 2024-03-14 | -$261.81M derived: sum of 3 quarters · filed 2024-03-14 | -$340.41M 10-K/A · filed 2024-03-14 | -$332.63M 10-K · filed 2023-02-28 | ||||
| 2022-09-30 | -$84.24M derived: 10-K 9 month − 10-K 6 month · filed 2024-03-14 | -$164.53M derived: sum of 2 quarters · filed 2024-03-14 | -$243.14M 10-K · filed 2024-03-14 | -$237.78M 10-Q · filed 2022-11-02 | -$243.05M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2022-06-30 | -$80.29M derived: 10-K 6 month − 10-K 3 month · filed 2024-03-14 | -$158.90M 10-K · filed 2024-03-14 | -$154.64M 10-Q · filed 2022-08-09 | -$158.81M derived: sum of 3 quarters · filed 2024-03-14 | -$237.00M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2022-03-31 | -$78.61M 10-K · filed 2024-03-14 | -$79.85M 10-Q · filed 2022-05-04 | -$78.52M derived: sum of 2 quarters · filed 2024-03-14 | -$156.71M derived: sum of 3 quarters · filed 2024-03-14 | -$227.64M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2021-12-31 | $86.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | -$78.10M derived: sum of 2 quarters · filed 2024-03-14 | -$149.04M derived: sum of 3 quarters · filed 2024-03-14 | -$182.05M 10-K/A · filed 2024-03-14 | -$257.00M 10-K · filed 2022-02-23 | ||||
| 2021-09-30 | -$78.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$149.12M derived: sum of 2 quarters · filed 2022-11-02 | -$182.14M 10-Q · filed 2022-11-02 | -$316.87M derived: sum of 4 quarters · filed 2024-03-14 | |||||
| 2021-06-30 | -$70.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$103.95M 10-Q · filed 2022-08-09 | -$238.68M derived: sum of 3 quarters · filed 2024-03-14 | -$304.88M derived: sum of 4 quarters · filed 2024-03-14 | |||||
| 2021-03-31 | -$33.02M 10-Q · filed 2022-05-04 | -$167.75M derived: sum of 2 quarters · filed 2024-03-14 | -$233.94M derived: sum of 3 quarters · filed 2024-03-14 | -$294.92M derived: sum of 4 quarters · filed 2024-03-14 | |||||
| 2020-12-31 | -$134.73M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | -$200.93M derived: sum of 2 quarters · filed 2024-03-14 | -$261.90M derived: sum of 3 quarters · filed 2024-03-14 | -$316.38M 10-K/A · filed 2024-03-14 | -$250.22M 10-K · filed 2021-02-25 | ||||
| 2020-09-30 | -$66.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$127.17M derived: sum of 2 quarters · filed 2021-11-04 | -$181.65M 10-Q · filed 2021-11-04 | -$242.68M derived: sum of 4 quarters · filed 2022-02-23 | |||||
| 2020-06-30 | -$60.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$115.45M 10-Q · filed 2021-08-04 | -$176.48M derived: sum of 3 quarters · filed 2022-02-23 | -$227.22M derived: sum of 4 quarters · filed 2022-02-23 | |||||
| 2020-03-31 | -$54.48M 10-Q · filed 2021-05-05 | -$115.51M derived: sum of 2 quarters · filed 2022-02-23 | -$166.25M derived: sum of 3 quarters · filed 2022-02-23 | -$207.49M derived: sum of 4 quarters · filed 2022-02-23 | |||||
| 2019-12-31 | -$61.03M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | -$111.77M derived: sum of 2 quarters · filed 2022-02-23 | -$153.01M derived: sum of 3 quarters · filed 2022-02-23 | -$184.59M 10-K · filed 2022-02-23 | |||||
| 2019-09-30 | -$50.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$91.98M derived: sum of 2 quarters · filed 2020-11-04 | -$123.56M 10-Q · filed 2020-11-04 | -$154.07M derived: sum of 4 quarters · filed 2021-02-25 | |||||
| 2019-06-30 | -$41.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$72.83M 10-Q · filed 2020-08-05 | -$103.34M derived: sum of 3 quarters · filed 2021-02-25 | -$146.84M derived: sum of 4 quarters · filed 2021-02-25 | |||||
| 2019-03-31 | -$31.59M 10-Q · filed 2020-05-06 | -$62.09M derived: sum of 2 quarters · filed 2021-02-25 | -$105.59M derived: sum of 3 quarters · filed 2021-02-25 | -$240.49M derived: sum of 4 quarters · filed 2021-02-25 | |||||
| 2018-12-31 | -$30.51M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$74.01M derived: sum of 2 quarters · filed 2021-02-25 | -$208.91M derived: sum of 3 quarters · filed 2021-02-25 | -$211.50M 10-K · filed 2021-02-25 | |||||
| 2018-09-30 | -$43.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$178.40M derived: sum of 2 quarters · filed 2019-11-05 | -$181.00M 10-Q · filed 2019-11-05 | ||||||
| 2018-06-30 | -$134.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$137.50M 10-Q · filed 2019-08-07 | |||||||
| 2018-03-31 | -$2.60M 10-Q · filed 2019-05-07 | ||||||||
| 2017-12-31 | -$2.00K 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |